From d8c2a277f153c3b1cd5aba0e77f771bc4cd025eb Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:49:11 +0000 Subject: [PATCH 1/2] extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 6 +++++ ...ients-undermining-chronic-use-economics.md | 6 +++++ ...copenia-glp1-muscle-loss-elderly-risk.json | 24 +++++++++++++++++++ ...arcopenia-glp1-muscle-loss-elderly-risk.md | 13 +++++++++- 4 files changed, 48 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2004090f..b96323e3 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -59,6 +59,12 @@ At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making i The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price. + +### Additional Evidence (challenge) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index e71c73f2..20997498 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -53,6 +53,12 @@ No data yet on whether payment model affects persistence—does being in an MA p The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested. + +### Additional Evidence (extend) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json new file mode 100644 index 00000000..9cc39a4c --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md index de9ecdae..0576f0f0 100644 --- a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md +++ b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md @@ -7,9 +7,13 @@ date: 2025-07-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: medium tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,10 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"] + + +## Key Facts +- Natural aging reduces skeletal muscle mass by 12-16% in elderly populations +- Sarcopenic obesity prevalence: 10-20% of older adults +- No pharmacological solution to GLP-1-induced muscle loss exists yet +- Next-generation GLP-1 compounds aim to improve 'quality of weight loss' by preserving muscle (per ADA) From c5805e75197acd0c97640682dd8b9475a47cbab0 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:49:30 +0000 Subject: [PATCH 2/2] auto-fix: strip 5 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...del makes the net cost impact inflationary through 2035.md | 4 ++-- ...etic-obesity-patients-undermining-chronic-use-economics.md | 2 +- ...cription-validating-futarchy-governed-capital-formation.md | 4 ++-- 3 files changed, 5 insertions(+), 5 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index b96323e3..ae2c85d5 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -49,13 +49,13 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir ### Additional Evidence (challenge) -*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* +*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16* At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated. ### Additional Evidence (challenge) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 20997498..3d9ef0bb 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -49,7 +49,7 @@ No data yet on whether payment model affects persistence—does being in an MA p ### Additional Evidence (extend) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested. diff --git a/domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md b/domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md index f2f9093f..86cfbaa7 100644 --- a/domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md +++ b/domains/internet-finance/metadao-ico-platform-demonstrates-15x-oversubscription-validating-futarchy-governed-capital-formation.md @@ -62,13 +62,13 @@ Cloak raised only $1,455 against a $300,000 target (0.5% of target), entering re ### Additional Evidence (challenge) -*Source: [[2026-03-05-futardio-launch-phonon-studio-ai]] | Added: 2026-03-16* +*Source: 2026-03-05-futardio-launch-phonon-studio-ai | Added: 2026-03-16* Phonon Studio AI launch failed to reach its $88,888 target and entered refunding status, demonstrating that not all futarchy-governed raises succeed. The project had demonstrable traction (live product, 1000+ songs generated, functional token mechanics) but still failed to attract sufficient capital, suggesting futarchy capital formation success is not uniform across project types or market conditions. ### Additional Evidence (extend) -*Source: [[2026-03-14-futardio-launch-nfaspace]] | Added: 2026-03-16* +*Source: 2026-03-14-futardio-launch-nfaspace | Added: 2026-03-16* NFA.space launched on futard.io with $125,000 target, demonstrating futarchy-governed fundraising for physical art RWA marketplace. Project has pre-existing traction: 1,895 artists from 79 countries, 2,000+ artworks sold, $150,000 historical revenue, $5,000 MRR, 12.5% repeat purchase rate. This shows futarchy ICO platform attracting projects with demonstrated product-market fit, not just speculative launches.